The Hill (Op-Ed): For Big Pharma, the revolving door keeps spinning
The revolving door is an age-old problem in Washington but the scope and volume of the conflicts in the current administration - starting with the president himself – is unprecedented and lends new urgency to legislative reforms pending in Congress. The “Executive Branch Conflict of Interest Act”(HR 599/S 156) would curb many of these abuses by mandating recusal periods, prohibiting employer bonuses to those leaving to take government positions, tightening lobbying rules and lengthening “cooling off” periods. Presidential conflicts of interest measures have also been introduced in both the House (HR 1481) and Senate (S 882). Provisions from these bills are also included in a sweeping set of reforms in the “For the People Act” (HR 1/S 949), which passed the House earlier this year.